Klozapin Tedavisi Sonrası Gelişen Lökositoz Olgusu

Objective & Hypothesis:Clozapine is an atypical antipsychotic drug that is approved by the US Food and Drug Administration (FDA) for the treatment of psychotic disorders.

📊

Key Findings & Data:Agranulocytosis is a well-established side effect of clozapine; clozapine has also been associated with other blood dyscrasias like leukocytosis, albeit rarely.

💡

Conclusion & Impact:In this paper, we aim to report a case of possible clozapine-associated leukocytosis in a 41-year-old woman

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Clozapine is an atypical antipsychotic drug that is approved by the US Food and Drug Administration (FDA) for the treatment of psychotic disorders. Agranulocytosis is a well-established side effect of clozapine; clozapine has also been associated with other blood dyscrasias like leukocytosis, albeit rarely. In this paper, we aim to report a case of possible clozapine-associated leukocytosis in a 41-year-old woman

Özet

Klozapin psikotik bozuklukların tedavisinde FDA (US Food and Drug Administration) onayına sahip bir antipsikotiktir. Klozapinin agranülosi-toza yol açabileceği çok iyi bilinmekle birlikte çok nadir olarak lökositoz gibi kan diskrazilerine de sebep olabilmektedir. Bu çalışmada yazarlar tarafından, klozapine bağlı geliştiği düşünülen lökositozu mevcut olan 41 yaşındaki bir olgunun paylaşılması amaçlanmıştır.

🔖

Cite This Article

IŞIK, A. Ö. P., ÇAKIR, U., GÜNDÜZ, N. (2016). Klozapin Tedavisi Sonrası Gelişen Lökositoz Olgusu. Nöropsikiyatri Arşivi, Cilt: 53 - Sayı: 1, 87–88. https://ajindex.com/articles/292433

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (3)

Marder SR, Hurford IM, van Kamen DP. Second-generation antipsychotics, Comprehensive Textbook of Psychiatry. Lippincott Williams and Wilkins, Phi- ladelphia 2009.
Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine rela- ted morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59:3-7. Gerson SL. Clozapine--deciphering the risks. N Engl J Med 1993; 329:204- 205. [CrossRef] Seifritz E, Hemmeter U, Holsboer-Trachsler, E, Pöldinger W. Chronic leuko- cytosis and neutrophilia caused by rehabilitation stress in a clozapine-treated patient. Pharmacopsychiatry 1993; 26:99. [CrossRef] Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, Kolb-Bachofen V, Klimke A. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 2005; 25:419- 426. [CrossRef] Lapierre G, Stewart RB. Lithium carbonate and leukocytosis. American Journal of Health-System Pharmacy 1980; 37:1525-1528.
Popli A, Pies R. Clozapine and leukocytosis. J Clin Psychopharmacol 1995; 15:286-287. [CrossRef] Trinidad ED, Potti A, Mehdi SA. Clozapine-induced blood dyscrasias. Haema- tologica 2000; 85(E-letters): E02. Madhusoodanan S, Cuni L, Brenner R, Sajatovic M, Palekar N, Amanbekova D. Chronic leukocytosis associated with clozapine: a case series. J Clin Psychiatry 2007; 68:484-488. [CrossRef] Sopko MA, Caley CF. Chronic leukocytosis associated with clozapine treat- ment. Clin Schizophr Relat Psychoses 2010; 4:141-144. [CrossRef] Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CY- P1A2 genotyped patients. Ther Drug Monit 2005; 27:539-543. [CrossRef] Carrillo JA, Herráiz AG, Ramos SI, Gervasini G, Vizcaíno S, Benítez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CY- P2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119-127.[CrossRef] 88